Compounds > floxuridine
Page last updated: 2024-08-17

floxuridine and 3',5'-o-dipalmitoyl-5-fluoro-2'-deoxyuridine

floxuridine has been researched along with 3',5'-o-dipalmitoyl-5-fluoro-2'-deoxyuridine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's5 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Scherphof, GL; Van Borssum Waalkes, M1
Hartmann, HR; Hengartner, H; Rubas, W; Schott, H; Schwendener, RA; Supersaxo, A; Weder, HG; Ziegler, A1
Huang, L; Kennel, SJ; Mori, A; Scherphof, GL; van Borssum Waalkes, M1
Huang, L; Kennel, SJ; Mori, A1
Morselt, H; Scherphof, GL; Sternberg, B; van Borssum Waalkes, M; van Galen, M1
Dontje, BH; Goris, H; Nijhof, W; Scherphof, G; Schwendener, RA; van Borssum Waalkes, M1

Other Studies

6 other study(ies) available for floxuridine and 3',5'-o-dipalmitoyl-5-fluoro-2'-deoxyuridine

ArticleYear
Liposome-incorporated 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine as a slow-release anti-tumor drug depot in rat liver macrophages.
    Selective cancer therapeutics, 1990,Spring, Volume: 6, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Division; Delayed-Action Preparations; Floxuridine; Kupffer Cells; Liposomes; Liver; Macrophages; Prodrugs; Tumor Cells, Cultured

1990
5'-O-Palmitoyl- and 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine--novel lipophilic analogues of 5'-fluoro-2'-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results.
    Biochemical and biophysical research communications, 1985, Jan-31, Volume: 126, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Floxuridine; Liposomes; Mice; Solubility

1985
Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
    Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Agents; Binding Sites, Antibody; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Female; Floxuridine; Immunohistochemistry; Liposomes; Lung; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Prodrugs; Tissue Distribution; Tumor Cells, Cultured

1995
Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
    Pharmaceutical research, 1993, Volume: 10, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Binding Sites; Cholesterol; Cytarabine; Cytidine Diphosphate Diglycerides; Doxorubicin; Drug Carriers; Floxuridine; Gangliosides; Liposomes; Male; Mice; Mice, Inbred BALB C; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Prodrugs; Surface Properties

1993
In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
    Biochimica et biophysica acta, 1993, May-14, Volume: 1148, Issue:1

    Topics: Antineoplastic Agents; Culture Media; Drug Carriers; Drug Stability; Floxuridine; Freeze Fracturing; Lipid Bilayers; Liposomes; Microscopy, Electron; Particle Size; Prodrugs; Tumor Cells, Cultured

1993
Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
    Anti-cancer drug design, 1998, Volume: 13, Issue:4

    Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Drug Carriers; Female; Floxuridine; Ileum; Injections, Intraperitoneal; Injections, Intravenous; Liposomes; Liver; Mice; Mice, Inbred BALB C; Organ Size; Prodrugs; Spleen

1998